Diaprost AB
About Diaprost AB
Diaprost's research and development is targeting prostate cancer with ambition to revolutionize personalized medicine. The goal is to establish an antibody platform, for both in vivo diagnostic, to simplify and make the identification/detection of prostate cancer more reliable, as well as for targeted therapeutics.YEAR FOUNDED:
2005
LEADERSHIP:
CEO: Johan Drott
5 articles about Diaprost AB
-
Diaprost Licenses its novel Theranostic Antibody, hu5A10, to Radiopharm Theranostics for Development in the Treatment and Diagnosis of Prostate Cancer.
9/28/2021
Diaprost announced that it has agreed terms for an exclusive Licensing Agreement with Radiopharm Theranostics ; an Australian based biotech startup, focused on building an innovative and differentiated pipeline of radiopharmaceutical products for both diagnostic and therapeutic uses.
-
Diaprost Announces Promising New Study for Patients with Metastatic PCa
2/22/2021
Diaprost announced a publication in the journal of Clinical Cancer Research on PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates.
-
Diaprost AB Acquires Rights to use of PSA Antibodies from Leading New York Cancer Center
8/25/2020
Diaprost announced that it has signed an exclusive license agreement with Memorial Sloan Kettering Cancer Center for IP related to the use of PSA antibodies for therapeutic and diagnostic purposes for prostate cancer.
-
Diaprost Announces Exercise of Option Under the Terms of its Research and Option Agreement With a Leading Pharmaceutical Company
1/21/2020
Diaprost entered into an exclusive Research and Option Agreement with a Top 10 Pharmaceutical company strategic partner in October 2017.
-
Diaprost Release: Study Demonstrates The Feasibility Of Targeting Human Kallikrein-Related Peptidase 2 (Hk2) For Detection And Monitoring Of Prostate Cancer
12/13/2016